metaPreg - Carbimazole, Thiamazole (Methimazole) during pregnancy

Carbimazole, Thiamazole (Methimazole)

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	1.40 [1.14, 1.72]	26%	13 studies	249,132	4,773	not evaluable	unclear
Major congenital malformations	1.78 [1.18, 2.69]	8%	7 studies	205	1,852	not evaluable	unclear
Genital anomalies	1.11 [0.75, 1.63]	0%	3 studies	25,766	2,856	not evaluable	critical
Limb defects	0.85 [0.65, 1.12]	0%	3 studies	74,533	2,856	not evaluable	critical
Respiratory system anomalies	1.62 [1.11, 2.37]	0%	3 studies	15,998	2,856	not evaluable	critical
Urinary malformations	1.69 [1.08, 2.67]	0%	3 studies	17,645	2,856	not evaluable	critical
Carbimazole embryopathy	14.62 [10.40, 20.55]	0%	6 studies	2,316	4,301	not evaluable	unclear
Eye defects	2.38 [1.21, 4.71]	0%	2 studies	2,493	1,736	not evaluable	critical
Congenital heart defects	1.73 [1.40, 2.15]	0%	3 studies	77,405	2,856	not evaluable	critical
Digestive system anomalies	2.99 [2.05, 4.36]	0%	3 studies	15,273	2,856	not evaluable	critical
Severe congenital heart defect	0.87 [0.25, 3.03]	0%	2 studies	739	1,311	not evaluable	unclear
Abdominal wall defects	5.44 [2.63, 11.23]	0%	2 studies	933	1,736	not evaluable	critical
Ear, face and neck anomalies	0.58 [0.08, 4.33]	0%	2 studies	912	1,736	not evaluable	critical
Nervous system anomalies	2.85 [1.39, 5.87]	0%	2 studies	5,852	1,282	not evaluable	critical
Omphalocele	9.70 [3.27, 28.78]	0%	3 studies	163	1,334	not evaluable	unclear
Syndromes and chromosomal abnormalities	1.16 [0.62, 2.17]	0%	2 studies	5,553	1,736	not evaluable	critical
Ano-rectal atresia and stenosis	1.77 [0.22, 14.34]	13%	2 studies	4	1,254	not evaluable	unclear
Atresia of bile ducts	2.94 [0.36, 24.10]	0%	2 studies	3	1,254	not evaluable	unclear
Cardiac septal defects	1.87 [1.14, 3.06]	-	1 study		1,097	not evaluable	critical
Congenital hydronephrosis	4.41 [0.48, 40.36]	0%	2 studies	3	1,254	not evaluable	unclear
Hypospadias	3.81 [0.32, 46.05]	0%	2 studies	1	1,254	not evaluable	unclear
Oro-facial clefts	1.54 [0.19, 12.70]	28%	2 studies	3,448	1,143	not evaluable	unclear
Other congenital malformations (Q80-84)	2.32 [0.38, 14.27]	50%	2 studies	2,022	1,736	not evaluable	critical
Ventricular septal defect	1.31 [0.56, 3.06]	0%	2 studies	25	1,254	not evaluable	unclear
Situs inversus	5.49 [0.58, 51.80]	0%	2 studies	25	1,311	not evaluable	unclear
Aplasia cutis congenita	23.36 [1.33, 409.42]	-	1 study	7	1,231	not evaluable	critical
Choanal atresia	25.89 [7.52, 89.13]	0%	2 studies	119	92	not evaluable	unclear
26 non statistically significant endpoints reported in only one study
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
Preterm (< 37 weeks)	1.21 [0.65, 2.23]	0%	4 studies	184	227	not evaluable	unclear
Low birth weight (< 2500g)	1.60 [0.46, 5.51]	25%	2 studies	141	80	not evaluable	unclear
1 non statistically significant endpoints reported in only one study
Maternal consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
Caesarean	-	-	0 study
3 non statistically significant endpoints reported in only one study
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
Goiter	0.96 [0.20, 4.60]	0%	3 studies	6	61	not evaluable	unclear
Hearing loss / Auditory deficit	3.68 [0.41, 32.73]	0%	2 studies	4	1,254	not evaluable	unclear
Hypothyroidism (fetal/neonatal)	0.88 [0.10, 7.50]	0%	3 studies	1	54	not evaluable	unclear
Hyperthyroidism / Thyrotoxicosis (fetal/neonatal)	0.77 [0.06, 9.94]	0%	2 studies	1	18	not evaluable	unclear
1 non statistically significant endpoints reported in only one study
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
Elective/induced termination of pregnancy	3.39 [1.80, 6.37]	0%	2 studies	46	1,550	not evaluable	unclear
Perinatal death	0.70 [0.25, 1.94]	0%	2 studies	16	1,550	not evaluable	unclear
Early intrauterine death (< 22 weeks)	3.94 [0.70, 22.25]	93%	2 studies	332	1,654	not evaluable	critical
Intrauterine deaths (as a whole or unspecified)	1.97 [0.89, 4.35]	0%	2 studies	26	131	not evaluable	unclear
Neuro-developmental disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
Neuro-developmental disorders (as a whole)	5.34 [2.17, 13.10]	-	1 study	692	20	not evaluable	NA
Cognitive developmental delay – children (3-6 years old)	0.34 [0.12, 0.95]	-	1 study		23	not evaluable	unclear
1 non statistically significant endpoints reported in only one study